文献速递头颈部肿瘤放疗

在口咽癌治疗中将分次效应与不均匀剂量分布纳入放射性骨坏死建模

Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment.
PubMed 文献 · Radiother Oncol · 2023-09-01

该回顾性队列研究纳入334例接受大分割立体定向体部放疗加量或常规调强放疗的口咽鳞癌患者,采用等效均匀剂量(EUD)建模预测下颌骨放射性骨坏死(ORN)。32例(9.6%)发生≥2级ORN,EUD(a=8)区分ORN的AUC为0.71;多变量回归中放疗前拔牙(SHR=2.34)、下颌骨体积(SHR=1.04)和EUD(a=8)(SHR=1.14)与ORN显著相关。结论认为经EUD校正分次与不均匀剂量后,单一模型可区分常规分次放疗与大分割加量治疗后的ORN与非ORN。

要点

  • 32例(9.6%)发生≥2级ORN,EUD(a=8)区分ORN的AUC=0.71。
  • 多变量回归中放疗前拔牙SHR=2.34、下颌骨体积SHR=1.04、EUD(a=8)SHR=1.14与ORN显著相关。
  • 基于常规DVH参数的ORN风险模型不能直接用于大分割立体定向体部放疗方案。

核心结论

  • 基于常规剂量体积直方图参数的ORN风险模型不能直接应用于大分割立体定向体部放疗的分次方案和剂量分布。
  • 使用EUD校正分次效应和不均匀剂量分布后,单一模型可区分常规分次放疗和大分割加量治疗后的ORN与非ORN。

研究设计与样本

  • 回顾性队列研究,纳入334例接受大分割立体定向体部放疗加量或常规调强放疗的口咽鳞状细胞癌患者。
  • ORN按CTCAE v5.0评分,两种方案的剂量分布转换为2 Gy分次等效剂量(α/β=0.85 Gy)并以EUD分析。
  • 选择能最佳区分≥2级ORN与非ORN的EUD参数a,采用单变量和多变量回归分析患者及治疗相关危险因素。

主要发现

  • 共32例患者(9.6%)发生≥2级ORN。
  • EUD(a=8)区分ORN与非ORN的AUC=0.71。
  • 多变量回归中,放疗前拔牙(SHR=2.34;p=0.012)、下颌骨体积(SHR=1.04;p=0.003)和EUD(a=8)(SHR=1.14;p<0.001)与ORN显著相关。

关键数值与推荐

  • ORN按CTCAE v5.0评分,≥2级ORN为终点。
  • 剂量转换为2 Gy分次等效剂量时采用α/β=0.85 Gy。
  • EUD参数a=8时对ORN与非ORN的区分最佳(AUC=0.71)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Osteoradionecrosis (ORN) of the mandible is a severe complication following radiotherapy (RT). With a renewed interest in hypofractionation for head and neck radiotherapy, more information concerning ORN development after high fraction doses is important. The aim of this explorative study was to develop a model for ORN risk prediction applicable across different fractionation schemes using Equivalent Uniform Doses (EUD). MATERIAL AND METHODS: We performed a retrospective cohort study in 334 oropharyngeal squamous cell carcinoma (OPSCC) patients treated with either a hypofractionated Stereotactic Body Radiation Therapy (HF-SBRT) boost or conventional Intensity Modulated Radiation Therapy (IMRT). ORN was scored with the CTCAE v5.0. HF-SBRT and IMRT dose distributions were converted into equivalent dose in 2 Gy fractions (α/β = 0.85 Gy) and analyzed using EUD. The parameter a that led to an EUD that best discriminated patients with and without grade ≥ 2 ORN was selected. Patient and treatment-related risk factors of ORN were analyzed with uni- and multivariable regression analysis. RESULTS: A total of 32 patients (9.6%) developed ORN grade ≥ 2. An EUD(a = 8) best discriminated between ORN and non-ORN (AUC = 0.71). In multivariable regression, pre-RT extractions (SHR = 2.34; p = 0.012), mandibular volume (SHR = 1.04; p = 0.003), and the EUD(a = 8) (SHR = 1.14; p < 0.001) were significantly associated with ORN. CONCLUSION: Risk models for ORN based on conventional DVH parameters cannot be directly applied to HF-SBRT fractionation schemes and dose distributions. However, after correcting for fractionation and non-uniform dose distributions using EUD, a single model can distinguish between ORN and non-ORN after conventionally fractionated radiotherapy and hypofractionated boost treatments.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Verduijn GM, Sijtsema ND, van Norden Y, et al. Accounting for fractionation and heterogeneous dose distributions in the modelling of osteoradionecrosis in oropharyngeal carcinoma treatment. Radiother Oncol. 2023. PMID: 37659662. doi:10.1016/j.radonc.2023.109889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。